Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C

Thomas F. Baumert, Sabine Wellnitz, Shigeaki Aono, Jujin Satoi, David Herion, J. Tilman Gerlach, Gerd R. Pape, Johnson Y N Lau, Jay H. Hoofnagle, Hubert E. Blum, T. Jake Liang

Research output: Contribution to journalArticle

Abstract

We recently described the efficient assembly of hepatitis C virus (HCV) structural proteins into HCV-like particles (HCV-LPs) in insect cells. These noninfectious HCV-LPs have similar morphologic and biophysical properties as putative virions isolated from HCV-infected humans and can induce a broadly directed immune response in animal models. The HCV envelope proteins of HCV-LPs are presumably presented in a native, virion-like conformation and may therefore interact with antienvelope antibodies directed against conformational epitopes. In this study, HCV-LPs were used as capture antigens in an enzyme-linked immunosorbent assay (ELISA) to detect and quantify antibodies against HCV structural proteins in patients with acute and chronic hepatitis C. High titers of anti-HCV-LP antibodies were detected in patients chronically infected with HCV genotypes 1 to 6. In contrast to individuals with chronic hepatitis C, patients with acute self-limited hepatitis C displayed only a transient and weak seroreactivity against HCV-LPs. Patients with chronic HCV infection successfully treated with interferon demonstrated a gradual decline of anti-HCV-LP titers during or subsequent to viral clearance. Sustained interferon responders were characterized by significantly higher pretreatment levels of anti-HCV-LP antibodies as compared with nonresponders (P = .0001). In conclusion, HCV infection is associated with limited humoral immunity against the envelope proteins present on the HCV-LPs. An HCV-LP-based ELISA may be a useful diagnostic tool to distinguish acute hepatitis C from chronic HCV infection with exacerbation, and to predict viral clearance in response to interferon.

Original languageEnglish (US)
Pages (from-to)610-617
Number of pages8
JournalHepatology
Volume32
Issue number3
StatePublished - 2000
Externally publishedYes

Fingerprint

Hepatitis C Antibodies
Chronic Hepatitis C
Hepacivirus
Virion
Virus Diseases
Interferons
Viral Structural Proteins
Hepatitis C
Enzyme-Linked Immunosorbent Assay
Viral Envelope Proteins
Humoral Immunity
Protein C
Viral Load

ASJC Scopus subject areas

  • Hepatology

Cite this

Baumert, T. F., Wellnitz, S., Aono, S., Satoi, J., Herion, D., Tilman Gerlach, J., ... Jake Liang, T. (2000). Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C. Hepatology, 32(3), 610-617.

Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C. / Baumert, Thomas F.; Wellnitz, Sabine; Aono, Shigeaki; Satoi, Jujin; Herion, David; Tilman Gerlach, J.; Pape, Gerd R.; Lau, Johnson Y N; Hoofnagle, Jay H.; Blum, Hubert E.; Jake Liang, T.

In: Hepatology, Vol. 32, No. 3, 2000, p. 610-617.

Research output: Contribution to journalArticle

Baumert, TF, Wellnitz, S, Aono, S, Satoi, J, Herion, D, Tilman Gerlach, J, Pape, GR, Lau, JYN, Hoofnagle, JH, Blum, HE & Jake Liang, T 2000, 'Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C', Hepatology, vol. 32, no. 3, pp. 610-617.
Baumert TF, Wellnitz S, Aono S, Satoi J, Herion D, Tilman Gerlach J et al. Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C. Hepatology. 2000;32(3):610-617.
Baumert, Thomas F. ; Wellnitz, Sabine ; Aono, Shigeaki ; Satoi, Jujin ; Herion, David ; Tilman Gerlach, J. ; Pape, Gerd R. ; Lau, Johnson Y N ; Hoofnagle, Jay H. ; Blum, Hubert E. ; Jake Liang, T. / Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C. In: Hepatology. 2000 ; Vol. 32, No. 3. pp. 610-617.
@article{0ab37cc1ccbb45099664ce76e73b712b,
title = "Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C",
abstract = "We recently described the efficient assembly of hepatitis C virus (HCV) structural proteins into HCV-like particles (HCV-LPs) in insect cells. These noninfectious HCV-LPs have similar morphologic and biophysical properties as putative virions isolated from HCV-infected humans and can induce a broadly directed immune response in animal models. The HCV envelope proteins of HCV-LPs are presumably presented in a native, virion-like conformation and may therefore interact with antienvelope antibodies directed against conformational epitopes. In this study, HCV-LPs were used as capture antigens in an enzyme-linked immunosorbent assay (ELISA) to detect and quantify antibodies against HCV structural proteins in patients with acute and chronic hepatitis C. High titers of anti-HCV-LP antibodies were detected in patients chronically infected with HCV genotypes 1 to 6. In contrast to individuals with chronic hepatitis C, patients with acute self-limited hepatitis C displayed only a transient and weak seroreactivity against HCV-LPs. Patients with chronic HCV infection successfully treated with interferon demonstrated a gradual decline of anti-HCV-LP titers during or subsequent to viral clearance. Sustained interferon responders were characterized by significantly higher pretreatment levels of anti-HCV-LP antibodies as compared with nonresponders (P = .0001). In conclusion, HCV infection is associated with limited humoral immunity against the envelope proteins present on the HCV-LPs. An HCV-LP-based ELISA may be a useful diagnostic tool to distinguish acute hepatitis C from chronic HCV infection with exacerbation, and to predict viral clearance in response to interferon.",
author = "Baumert, {Thomas F.} and Sabine Wellnitz and Shigeaki Aono and Jujin Satoi and David Herion and {Tilman Gerlach}, J. and Pape, {Gerd R.} and Lau, {Johnson Y N} and Hoofnagle, {Jay H.} and Blum, {Hubert E.} and {Jake Liang}, T.",
year = "2000",
language = "English (US)",
volume = "32",
pages = "610--617",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C

AU - Baumert, Thomas F.

AU - Wellnitz, Sabine

AU - Aono, Shigeaki

AU - Satoi, Jujin

AU - Herion, David

AU - Tilman Gerlach, J.

AU - Pape, Gerd R.

AU - Lau, Johnson Y N

AU - Hoofnagle, Jay H.

AU - Blum, Hubert E.

AU - Jake Liang, T.

PY - 2000

Y1 - 2000

N2 - We recently described the efficient assembly of hepatitis C virus (HCV) structural proteins into HCV-like particles (HCV-LPs) in insect cells. These noninfectious HCV-LPs have similar morphologic and biophysical properties as putative virions isolated from HCV-infected humans and can induce a broadly directed immune response in animal models. The HCV envelope proteins of HCV-LPs are presumably presented in a native, virion-like conformation and may therefore interact with antienvelope antibodies directed against conformational epitopes. In this study, HCV-LPs were used as capture antigens in an enzyme-linked immunosorbent assay (ELISA) to detect and quantify antibodies against HCV structural proteins in patients with acute and chronic hepatitis C. High titers of anti-HCV-LP antibodies were detected in patients chronically infected with HCV genotypes 1 to 6. In contrast to individuals with chronic hepatitis C, patients with acute self-limited hepatitis C displayed only a transient and weak seroreactivity against HCV-LPs. Patients with chronic HCV infection successfully treated with interferon demonstrated a gradual decline of anti-HCV-LP titers during or subsequent to viral clearance. Sustained interferon responders were characterized by significantly higher pretreatment levels of anti-HCV-LP antibodies as compared with nonresponders (P = .0001). In conclusion, HCV infection is associated with limited humoral immunity against the envelope proteins present on the HCV-LPs. An HCV-LP-based ELISA may be a useful diagnostic tool to distinguish acute hepatitis C from chronic HCV infection with exacerbation, and to predict viral clearance in response to interferon.

AB - We recently described the efficient assembly of hepatitis C virus (HCV) structural proteins into HCV-like particles (HCV-LPs) in insect cells. These noninfectious HCV-LPs have similar morphologic and biophysical properties as putative virions isolated from HCV-infected humans and can induce a broadly directed immune response in animal models. The HCV envelope proteins of HCV-LPs are presumably presented in a native, virion-like conformation and may therefore interact with antienvelope antibodies directed against conformational epitopes. In this study, HCV-LPs were used as capture antigens in an enzyme-linked immunosorbent assay (ELISA) to detect and quantify antibodies against HCV structural proteins in patients with acute and chronic hepatitis C. High titers of anti-HCV-LP antibodies were detected in patients chronically infected with HCV genotypes 1 to 6. In contrast to individuals with chronic hepatitis C, patients with acute self-limited hepatitis C displayed only a transient and weak seroreactivity against HCV-LPs. Patients with chronic HCV infection successfully treated with interferon demonstrated a gradual decline of anti-HCV-LP titers during or subsequent to viral clearance. Sustained interferon responders were characterized by significantly higher pretreatment levels of anti-HCV-LP antibodies as compared with nonresponders (P = .0001). In conclusion, HCV infection is associated with limited humoral immunity against the envelope proteins present on the HCV-LPs. An HCV-LP-based ELISA may be a useful diagnostic tool to distinguish acute hepatitis C from chronic HCV infection with exacerbation, and to predict viral clearance in response to interferon.

UR - http://www.scopus.com/inward/record.url?scp=0033840190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033840190&partnerID=8YFLogxK

M3 - Article

C2 - 10960457

AN - SCOPUS:0033840190

VL - 32

SP - 610

EP - 617

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 3

ER -